Jasvinder Singh
Rheumatology · Houston, TXNPI 1780692871
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,213 of the $16,478 with a category attached, or 86.3%. ANI Pharmaceuticals, Inc. accounts for 80.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $13,364 and has fallen 99.9% since, to $18 in 2025.
Across 19 payments — averaging $867.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ANI Pharmaceuticals, Inc.$13K
- Amgen$3K
- Abbott$155
- Recor Medical Inc$150
- Boehringer Ingelheim$39
- AbbVie$18
- plus $18 from 1 others
Across 8 payments — averaging $636.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Zimmer Biomet$5K
What the payments were for
- Speaking & faculty fees$14,21386%
- Travel & lodging$1,5559%
- Food & beverage$7104%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 11 | $13,325 |
| Amgen | 3 | $2,772 |
| Abbott | 1 | $155 |
| Recor Medical Inc | 1 | $150 |
| Boehringer Ingelheim | 1 | $39 |
| AbbVie | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,478 in reported general payments places this provider in the 75th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 29 | $268,024 |
| Humira(Cf) PenAdalimumab | 17 | $114,686 |
| BenlystaBelimumab | 13 | $58,922 |
| Actemra ActpenTocilizumab | 14 | $30,921 |
| Hydroxychloroquine Sulfate | 64 | $3,431 |
| MethotrexateMethotrexate Sodium | 17 | $1,089 |
| Allopurinol | 16 | $665 |
| Diclofenac Sodium | 12 | $414 |
| Methylprednisolone | 12 | $109 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Houston
- Naureen AlimHouston$397K
- Shervin AssassiHouston$329K
- Tareq Abou-KhamisHouston$116K
- Maureen MayesHouston$84K
- Maria Suarez AlmazorHouston$72K
- John ReveilleHouston$61K
- Michelle EisenbergHouston$53K
- Alfredo SardinasHouston$52K
- Adnan PeerHouston$49K
- Mujahed AlikhanHouston$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.